Categories: News

CENTR Brands Corp. Announces Q2 2022 Results

Vancouver, British Columbia–(Newsfile Corp. – January 28, 2022) – CENTR Brands Corp. (CSE: CNTR) (FSE: 303) (OTCQB: CNTRF) (the “Company“) today announced its financial results for the quarter ended August 31, 2021. Selected comparative financial information is set forth below with the full financial statements for the quarter and the related management’s discussion and analysis (“MD&A“) available under the Company’s SEDAR profile at www.sedar.com. All amounts are expressed in United States Dollars, unless otherwise stated:

Q2
2022
Q2
2021
Gross sales 373,319 417,064
Net sales 298,799 317,845
Net income (loss) and comprehensive income (loss) for the period (1) 834,512 (752,354)
Basic and diluted income
(loss) per share
0.01 (0.01)

 
(1) Q2 2022’s net income and comprehensive income for the period includes non-cash gains of $2,320,419 for the revaluation of warrants as a liability for accounting purposes.

Consumers can visit CENTR’s online store at: www.findyourcentr.com/shop.

About CENTR Brands Corp.

CENTR Brands Corp. is one of North America’s leading functional beverage companies. CENTR develops and markets non-alcoholic, functional ingestibles for the global market. The Company produces CENTR and CENTR Sugar Free, both sparkling, low calorie, CBD beverages as well as CENTR Instant, a family of on-the-go CBD powders. For more information visit www.findyourcentr.com, and follow on Instagram at @findyourcentr.

For further information, contact media@findyourcentr.com.

On behalf of the Board,

CENTR BRANDS CORP.

/s/ Joseph Meehan
Joseph Meehan, Chief Executive Officer

This press release may contain “Forward-Looking Statements” within the meaning of applicable Canadian securities laws. Actual results may differ from those indicated as a result of finalization of the Company’s financial statements as well as other risks and uncertainties. Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements and information other than as required by applicable laws, rules and regulations.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/112044

Staff

Recent Posts

CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026

CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…

4 hours ago

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

7 hours ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

7 hours ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

7 hours ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

7 hours ago

RxAnte Announces Strategic Growth Investment from Primus Capital

PORTLAND, Maine, Jan. 12, 2026 /PRNewswire/ -- RxAnte, the leading provider of analytics, software, and…

7 hours ago